Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

PHARMACIE BOURDIN-CROS : revenue, balance sheet and financial ratios

PHARMACIE BOURDIN-CROS is a French company founded 10 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in NARBONNE (11100), this company of category PME shows in 2025 a net income positive of 324 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE BOURDIN-CROS (SIREN 818524043)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net income 323 889 € 237 096 € 480 471 € 880 537 € 459 183 € 370 770 € 164 305 € 196 252 € 98 408 €
EBITDA N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, PHARMACIE BOURDIN-CROS generates positive net income of 324 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 98 k€ -> 324 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

323 889 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

29.451%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

41.053%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

38.0%

Solvency indicators evolution
PHARMACIE BOURDIN-CROS

Sector positioning

Debt ratio
29.45 2025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Good -10 pts over 3 years

In 2025, the debt ratio of PHARMACIE BOURDIN-CROS (29.45) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
41.05% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Average -16 pts over 3 years

In 2025, the financial autonomy of PHARMACIE BOURDIN-CROS (41.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 110.77. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

110.766

Liquidity indicators evolution
PHARMACIE BOURDIN-CROS

Sector positioning

Liquidity ratio
110.77 2025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Watch -25 pts over 3 years

In 2025, the liquidity ratio of PHARMACIE BOURDIN-CROS (110.77) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Positioning of PHARMACIE BOURDIN-CROS in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of PHARMACIE BOURDIN-CROS is estimated at 5 145 015 € (range 3 491 431€ - 8 073 237€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
3491k€ 5145k€ 8073k€
5 145 015 € Range: 3 491 431€ - 8 073 237€
NAF 5 année 2025

Valuation method used

Net Income Multiple
323 889 € × 15.9x = 5 145 015 €
Range: 3 491 432€ - 8 073 237€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE BOURDIN-CROS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE BOURDIN-CROS

What is the revenue of PHARMACIE BOURDIN-CROS ?

The revenue of PHARMACIE BOURDIN-CROS is not publicly disclosed (confidential accounts filed with INPI).

Is PHARMACIE BOURDIN-CROS profitable?

Yes, PHARMACIE BOURDIN-CROS generated a net profit of 324 k€ in 2025.

Where is the headquarters of PHARMACIE BOURDIN-CROS ?

The headquarters of PHARMACIE BOURDIN-CROS is located in NARBONNE (11100), in the department Aude.

Where to find the tax return of PHARMACIE BOURDIN-CROS ?

The tax return of PHARMACIE BOURDIN-CROS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE BOURDIN-CROS operate?

PHARMACIE BOURDIN-CROS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.